Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Oh J et al. | Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). | 2017 | Diabetes Obes Metab | pmid:27761990 |
Kanebratt KP et al. | Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. | 2008 | Clin. Pharmacol. Ther. | pmid:18650803 |
Shin KH et al. | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | 2013 | Clin. Pharmacol. Ther. | pmid:23784264 |
Tomalik-Scharte D et al. | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | 2009 | Clin. Pharmacol. Ther. | pmid:19458613 |
Wollmann BM et al. | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. | 2017 | Clin Transl Sci | pmid:27991741 |
Jiang X et al. | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. | 2017 | Clin Pharmacol Drug Dev | pmid:27138546 |
DeGorter MK et al. | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. | 2013 | Circ Cardiovasc Genet | pmid:23876492 |
Goodenough AK et al. | Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. | 2011 | Chem. Res. Toxicol. | pmid:21728364 |
Higashi T et al. | LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. | 2013 | Chem. Pharm. Bull. | pmid:23449202 |
Gjestad C et al. | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | 2016 | Br J Clin Pharmacol | pmid:26574235 |